Figure 4.

LNP Increases Anticancer Efficacy of VA in Liver Cancer

(A) A diagram of lipid nanoparticle-encapsulated VA (LV) with double-layer structure composed by PEG bad egg/cholesterol/DODMA. (B) Compared to the VA-treated group, the increased anti-cell proliferation effect was only detected for HCC cell lines Hep3B and SNU-449 but not for hepatoblastoma cell HepG2. (C) Relative inhibition rates were calculated by comparing the OD value of LV to NC at the concentration of 850 μM of LV, which gives over 30% inhibitory rates for liver cancer cells Hep3B and SNU-449 and less than 10% for normal liver cell THLE-3. Data are presented as the mean ± SD; NS, not significant; NC, negative control. ∗p < 0.05; ∗∗p < 0.01;∗∗∗p < 0.001.